That means zero lives lost too soon, and zero families left behind.

For some cancers, we are getting closer to that goal, but for too many, we still remain too far away. With one in two people expected to be diagnosed with cancer in their lifetime, the need for action has never been greater.

We are living in a golden age of science. Advances in diagnostics, genomics, artificial intelligence and precision medicine are transforming what is possible in cancer care, and the UK is at the forefront of this progress.

But innovation alone is not enough. To improve outcomes, we must ensure these advances reach patients consistently, equitably and at scale.

That's why Cancer: Project Zero is entering its next chapter.

Through Road to Zero, we are bringing together healthcare leaders, policymakers, clinicians and industry to explore the practical changes needed to turn scientific innovation into real-world impact, helping deliver better cancer outcomes for patients across the UK.

You can also explore our first Cancer: Project Zero Essay Compendium for a collection of expert essays exploring innovation, AI, personalised care and the future of cancer care.

We are the UK’s leading Biopharmaceutical company

Through a series of expert essays, Road to Zero brings together leading voices from across healthcare to explore the ideas, policies and partnerships shaping the future of cancer care. Together, they examine the practical action needed to move from ambition to delivery – and ultimately improve outcomes across the UK.

Be sure to tune in.